Telling Progress from Hype, and Where to Follow It
3 / 3
Look at the two columns as two ways of describing the very same result. The credible version names the compound, gives the phase and the number of patients, says what was measured and against what comparison, and admits what is still unknown. The promotional version leads with a percentage, uses the word cure without a patient outcome, and treats model accuracy as if it were a clinical result. The difference is not the science; it is whether the claim can be checked. So when you meet a headline, ask three things: what was actually tested, in how many people, and compared against what. If the honest answer is that a model did well on historical data, you are looking at a research result, not a treatment. To follow the field yourself, trial registries show what is genuinely running in people, peer-reviewed journals publish the methods and the caveats, and company pipeline pages reveal which candidates advanced and which quietly stopped.
0:00 / 0:00
How the same result reads two ways
Credible progress
Names the specific compound or trial
States the phase and the number of patients
Says what was measured and against what comparison
States the limitations openly
Hype
Leads with a percentage and no context
Uses 'cure' or 'breakthrough' without a patient outcome
Cites model accuracy as if it were a clinical result
Omits what is still unknown
Three questions to ask of any headline
What exactly was tested — a model, a molecule, or a treatment in people?
In how many people, and were they representative of the patients who would actually use it?
Compared against what — an existing treatment, a placebo, or nothing at all?
Where to follow the field
Trial registries: what is actually running and still recruiting in people
Peer-reviewed journals: results published with methods and stated limitations
Company pipeline pages and conference presentations: which candidates moved forward and which stopped
